[go: up one dir, main page]

MX2023000577A - Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa. - Google Patents

Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa.

Info

Publication number
MX2023000577A
MX2023000577A MX2023000577A MX2023000577A MX2023000577A MX 2023000577 A MX2023000577 A MX 2023000577A MX 2023000577 A MX2023000577 A MX 2023000577A MX 2023000577 A MX2023000577 A MX 2023000577A MX 2023000577 A MX2023000577 A MX 2023000577A
Authority
MX
Mexico
Prior art keywords
atr kinase
compound used
kinase inhibitor
pyrazolopyrimidine compound
compound
Prior art date
Application number
MX2023000577A
Other languages
English (en)
Inventor
Bin Liu
Jing Li
Yanping Zhao
Hongjun Wang
Cheung Ling Cheng
Weiting Zhong
Huifen Xu
Chuangchuang Huang
Weina Liu
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of MX2023000577A publication Critical patent/MX2023000577A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se divulga un compuesto de fórmula general (I), el cual puede usarse para el tratamiento de enfermedades mediadas por ATR cinasa, por ejemplo, enfermedades proliferativas, tal como cáncer. Se divulgan además un método de preparación para el compuesto de la fórmula general (I), una composición farmacéutica, y el uso de la composición farmacéutica para el tratamiento de enfermedades mediadas por ATR cinasa. (ver formula I).
MX2023000577A 2020-07-13 2021-07-13 Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa. MX2023000577A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010669088 2020-07-13
CN202011163505 2020-10-27
PCT/CN2021/105867 WO2022012484A1 (zh) 2020-07-13 2021-07-13 作为atr激酶抑制剂的吡唑并嘧啶化合物

Publications (1)

Publication Number Publication Date
MX2023000577A true MX2023000577A (es) 2023-03-23

Family

ID=79274460

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000577A MX2023000577A (es) 2020-07-13 2021-07-13 Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa.

Country Status (12)

Country Link
US (1) US20230271968A1 (es)
EP (1) EP4166556A4 (es)
JP (1) JP2023534676A (es)
KR (1) KR20230039675A (es)
CN (2) CN113929688B (es)
AU (1) AU2021310000A1 (es)
BR (1) BR112023000654A2 (es)
CA (1) CA3185963A1 (es)
IL (1) IL299804A (es)
MX (1) MX2023000577A (es)
TW (1) TW202202506A (es)
WO (1) WO2022012484A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7744350B2 (ja) 2020-01-13 2025-09-25 バージ アナリティクス，インコーポレイテッド 置換ピラゾロ－ピリミジンおよびその使用
CA3187915A1 (en) * 2020-08-07 2022-02-10 Antengene Discovery Limited Atr inhibitors and uses thereof
US20250101040A1 (en) * 2022-01-18 2025-03-27 Jiangsu Yayo Biotechnology Co., Ltd. New type pyrazolopyrimidine compound and composition thereof, preparation method therefor and use thereof
CN120718043A (zh) * 2024-03-28 2025-09-30 励缔(杭州)医药科技有限公司 具有mTOR抑制活性的有机化合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
SA111320519B1 (ar) * 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
EP2723745A1 (en) * 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2742046A1 (en) * 2011-08-12 2014-06-18 F.Hoffmann-La Roche Ag PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE
TR201807740T4 (tr) * 2012-12-07 2018-06-21 Vertex Pharma ATR kinaz inhibitörü olarak 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid.
TWI656121B (zh) * 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
IL281212B2 (en) * 2018-09-07 2023-12-01 Merck Patent Gmbh 5-Morpholin-4-yl-pyrazolo[4,3-B]pyridine derivatives and their use
KR20210097124A (ko) * 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用

Also Published As

Publication number Publication date
CN115943145A (zh) 2023-04-07
IL299804A (en) 2023-03-01
AU2021310000A1 (en) 2023-03-02
BR112023000654A2 (pt) 2023-04-25
JP2023534676A (ja) 2023-08-10
EP4166556A4 (en) 2024-06-26
EP4166556A1 (en) 2023-04-19
US20230271968A1 (en) 2023-08-31
CA3185963A1 (en) 2022-01-20
CN113929688B (zh) 2024-05-10
TW202202506A (zh) 2022-01-16
WO2022012484A1 (zh) 2022-01-20
CN113929688A (zh) 2022-01-14
KR20230039675A (ko) 2023-03-21

Similar Documents

Publication Publication Date Title
MX2023000577A (es) Compuesto de pirazolopirimidina usado como inhibidor de atr cinasa.
MX2024001893A (es) Compuestos heterociclicos y metodos de uso.
MX2023012726A (es) Compuestos heterociclicos y metodos de uso.
PH12022552739A1 (en) Fused tricyclic kras inhibitors
MX2025003821A (es) Compuestos con actividad contra tumores mutantes de kras
ZA202102999B (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
MX2025011774A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
WO2019152419A8 (en) Prc2 inhibitors
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023003576A (es) Compuesto como inhibidor de la akt cinasa.
WO2023078333A8 (zh) 一种取代的苯丙酸衍生物及其用途
EP4497438A3 (en) Tricyclic parp1 inhibitors and uses thereof
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
PH12022551623A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
MX2022015813A (es) 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
JOP20220107A1 (ar) مثبطات egfr تفارغية وطرق استخدامها
MX2023006845A (es) Inhibidores de la cinasa 5 similar al receptor de activina (alk-5) y usos de los mismos.
MY206262A (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
AU2018284249A1 (en) Aminothiazole compounds as protein kinase inhibitors
WO2023102162A8 (en) Novel hdac inhibitors and therapeutic use thereof
MX2024013266A (es) Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina
WO2025049274A3 (en) Tetracyclic derivatives, compositions and methods thereof